SANTA CLARA, Calif., July 19 /PRNewswire/ -- Applied Imaging Corp.
(Nasdaq: AICX) today announced that the U.S. Patent and Trademark Office (PTO)
has issued Patent No. 6,087,134 entitled "Method for Analyzing DNA from a Rare
Cell in a Cell Population."  The newly issued patent relates to a method of
isolating and subsequently analyzing the DNA in single cells (including cancer
cells) from a larger population of normal cells.  The isolation and analysis
of single cancer cells is critically important in cancer research for the
discovery of genes involved in the disease as well as in the identification of
new cancer markers.
    Applied Imaging CEO Dr. Jack Goldstein stated, "This innovative technology
greatly augments the analysis capabilities of our new instruments developed
for cancer pathology.  Using this technology with our MDS(TM) automated
imaging system, single cancer cells can be identified and isolated from a
population of normal cells.  Cancer researchers can then perform molecular
analyses, including polymerase chain reaction (PCR) and other studies, on
purified cancer cell populations rather than on mixed cell populations."
    Applied Imaging Corp., based in Santa Clara, California, is the leading
supplier of automated imaging systems utilized in genetics and pathology
laboratories for the analysis of chromosomes in cancer and prenatal disorders.
The Company has expanded its efforts in scanning and imaging applications in
the cancer pathology field.  Applied Imaging has installed over 1800 systems
in 800 laboratories in more than 35 countries.
    This press release contains forward looking statements as defined in the
Private Securities Litigation Reform Act of 1995, regarding, among other
matters, the Company's future financial performance as well as its research
and development and product development efforts.  Forward looking statements
address matters that are subject to a number of risks and uncertainties,
including the uncertainty of clinical studies and regulatory approvals.
Actual results could differ materially from those projected in the
forward-looking statement as a result of a number of factors including the
failure of the Company to successfully develop and commercialize its
micrometastasis or genetic instrument business, and other such factors as set
forth in the Company's form 10K for the year ended December 31, 1999 as filed
with the Securities and Exchange Commission.
    For additional information on Applied Imaging via fax, please dial
1-800-PRO-INFO, (732-544-2850 outside of the U.S.), code AICX.

Link to this page: